Neurofit to Showcase 'Comprehensive Dementia Drug Analysis Solution' at AAIC 2024

Neurofit, a brain disease imaging artificial intelligence (AI) solution company, announced on the 25th that it will participate in the 2024 Alzheimer's Association International Conference (AAIC 2024) held in Philadelphia, USA.

Image of Neurofit participating in the Alzheimer's Association International Conference (AAIC 2024)
[Photo by Neurofit]

AAIC is the largest international conference related to dementia science and clinical practice. Dementia experts, including researchers and clinicians from around the world, gather to share research and clinical education on the diagnosis, risk reduction, and treatment improvement of Alzheimer's disease and other dementias. This year, it will be held in Philadelphia, USA, for five days from the 28th (local time) to the 1st of next month.

At this conference, Neurofit plans to launch Neurofit Aqua AD, a cutting-edge brain imaging analysis technology related to Alzheimer's disease treatments. This software can monitor the therapeutic effects and side effects of anti-amyloid treatments and is preparing for medical device certification in major countries including Korea, the USA, and Japan. Neurofit will demonstrate the Neurofit Aqua AD product demo through a booth exhibition. Alongside this, they will also showcase Neurofit ScalePET, a positron emission tomography (PET) image quantitative analysis software with updated key features.

Following Eisai and Biogen's Leqembi, Eli Lilly's new drug Kisunla (generic name Donanemab) recently received approval from the U.S. Food and Drug Administration (FDA), and the Alzheimer's disease treatment market is expected to grow rapidly. However, these anti-amyloid treatments carry the risk of amyloid-related imaging abnormalities (ARIA) side effects such as brain hemorrhage and brain edema during treatment. In fact, ARIA was reported in 20-30% of patients participating in clinical trials of these drugs. Therefore, regulatory agencies in various countries recommend that patients using these drugs undergo 5 to 6 magnetic resonance imaging (MRI) scans annually.

Neurofit Aqua AD can quantitatively analyze MRI and PET images necessary during such treatment processes. It assesses patient eligibility before administration, monitors ARIA side effects during treatment, and after administration, it can analyze the therapeutic effects based on the reduction of amyloid-beta protein accumulated in the brain.

Bin Jungil, CEO of Neurofit, said, “AAIC is a conference where leading Alzheimer's disease scholars from around the world gather to share the latest knowledge, making it the most suitable venue for unveiling Neurofit’s ambitiously prepared total solution for Alzheimer's disease treatments.” He added, “With Kisunla following Leqembi’s release, we expect the utilization of Neurofit Aqua AD’s treatment-specialized brain imaging analysis technology to increase significantly.”

This content was produced with the assistance of AI translation services.